aztreonam has been researched along with cefuzonam in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ishii, Y; Matsuzawa, H; Mura, K; Oishi, M; Sakai, H; Shimizu-Ibuka, A; Yamada, S | 1 |
Hibi, S; Imashuku, S; Nakajima, F; Takaya, K; Todo, S | 1 |
1 review(s) available for aztreonam and cefuzonam
Article | Year |
---|---|
[Recombinant human granulocyte-colony stimulating factor (rhG-CSF) treatment for spleen abscess and periostitis in a patient with chronic granulomatous disease].
Topics: Abscess; Aztreonam; Ceftizoxime; Child; Chloramphenicol; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Granulomatous Disease, Chronic; Humans; Infusions, Intravenous; Male; Periostitis; Recombinant Proteins; Splenic Diseases | 1992 |
1 other study(ies) available for aztreonam and cefuzonam
Article | Year |
---|---|
Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Binding Sites; Cefotaxime; Escherichia coli; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Sequence Homology, Amino Acid; Structure-Activity Relationship; Substrate Specificity | 2011 |